Skip to main content
Explore URMC

menu

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Research Question:
Does the drug gantenerumab help patients with Alzheimer's disease?

Basic Study Information

Purpose:
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Location: University of Rochester

Study Contact Information

Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search